Eusa Pharma prostate cancer technology shows long-term efficacy

Eusa Pharma has highlighted newly-published data that illustrates the long-term benefits offered by Prostacint, its fusion imaging technology for prostate cancer treatment.

The International Journal of Radiation Oncology Biology Physics has published findings from a ten-year study, conducted among 236 patients undergoing radiotherapy for the cancer.

It was found that using Prostacint as a means of defining tumour stage and enabling image-guided radiotherapy can help to improve survival rates among sufferers in the long term.

Additionally, Eusa Pharma's innovation was shown to have uses as a predictive tool, facilitating the identification of patients who require more aggressive treatment or additional post-therapy monitoring.

Jim Mitchum, US president of EUSA Pharma, said: "This highly significant ten-year outcomes data demonstrates that Prostacint fusion imaging can accurately identify otherwise hidden nodal metastases, leading to better treatment decisions and therefore better outcomes for patients."

In September 2010, the company announced the appointment of Stephen Stamp, formerly of Shire and K-V Pharmaceutical, as a new independent non-executive director.